Roche Halts Development of Obesity Drug Candidate

Roche has halted development of its obesity drug candidate, a decision that will disappoint patients waiting for a new therapy and unsettle investors counting on the company’s pipeline growth. The move removes the prospect of a muscle‑preserving treatment—identified as Gym329 or emugrobart—from the upcoming market. Earlier reports had suggested the antibody could address weight loss while maintaining lean mass, raising hopes among clinicians.

Fierce Biotech reported the program was dropped after the interim results failed to achieve the required endpoints, and Endpoints News confirmed Roche has returned the license to Chugai Pharmaceutical. Chugai, which originally licensed the molecule, said it will resume development of the candidate for spinal muscular atrophy, shifting focus away from obesity. FirstWord highlighted the setback as a blow to Roche’s obesity pipeline, while TradingView noted the licensing reversal and the continuation of the asset under Chugai’s control.

Together, the reports outline the chain of actions following the halt. The open question now is whether Chugai’s refocused effort on SMA will revive the asset and how the pause reshapes the broader obesity‑drug market, including potential reallocation of R&D resources and investor sentiment toward Roche’s remaining pipeline.